SCHEMBL5401099

SCHEMBL5401099

CCc1nc(OC)c(NC(=O)N2CCN(c3cccc(O)c3)CC2)cc1C(=O)Nc1cc(CO)cc(Nc2c3ccccc3nc3ccccc23)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 7/20 0.42
TOP2B Q02880 7/20 0.42
GAA P10253 2/20 0.38
KMT2A Q03164 2/20 0.38
HTR7 P34969 1/20 0.38
HTR1A P08908 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
HCAR2 Q8TDS4 4/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
HSD17B10 Q99714 1/20 0.37
P2RY12 Q9H244 1/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TRPV1 Q8NER1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5391006 0.95 TOP2A (0.44) TOP2ATOP2BGAAKMT2AHTR1A
SCHEMBL5399361 0.94 TOP2A (0.41) TOP2ATOP2BGAAKMT2AHTR7
SCHEMBL5393960 0.92 TOP2A (0.43) TOP2ATOP2BGAAKMT2AHTR1A
SCHEMBL5398763 0.91 TOP2A (0.42) TOP2ATOP2BKMT2AHTR1AHTR1D
SCHEMBL5401707 0.91 TOP2A (0.42) TOP2ATOP2BGAAKMT2AHTR1A
SCHEMBL5401644 0.91 TOP2A (0.42) TOP2ATOP2BKMT2AHTR1AHTR1D
SCHEMBL5395198 0.90 TOP2A (0.41) TOP2ATOP2BHTR1AHTR1DHTR1B
SCHEMBL5485333 0.85 TOP2A (0.42) TOP2ATOP2BGAAKMT2AMAPT
SCHEMBL5440036 0.85 TOP2A (0.41) TOP2ATOP2BGAAKMT2AHTR1A
SCHEMBL5396710 0.80 HCAR2 (0.48) GAAKMT2AHCAR2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7230105-B2 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2007-06-12 US disclosed
US-20050222167-A1 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2005-10-06 US disclosed
EP-1487799-A4 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARM CO LTD (KR) 2005-06-01 EP disclosed
EP-1487799-A1 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2004-12-22 EP disclosed
WO-2003074490-A1 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222167-A1 9-aminoacridine derivatives and process for the preparation thereof PARP9, CASP9, AMPD2 TOP2A 131/4885TOP2B 209/4885GAA 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.